Capricor Therapeutics' stock drops 8.4% after significant surge in previous session.

Capricor Therapeutics shares fall 8.4% premarket after a nearly five-fold jump in the previous session. The biotechnology company is developing transformative cell and exosome-based therapeutics for rare diseases, with its lead product candidate, CAP-1002, advancing through Phase 3 clinical development for Duchenne muscular dystrophy treatment. The company's exosome technology is also in preclinical development for various disease treatments.